Area of research
Genetics · Oncology
Research interest
Research interests include Virus-based gene therapy research, CAR-T cell therapy research, Cancer Research and Treatments, and Parvovirus B19 Infection Studies.
The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics
H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma
The Multifaceted Role of Protoparvoviruses in Human Cutaneous T Cell Lymphoma: From Candidate Causative Agents to Potential Oncolytic Virus Therapeutics
Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells
Generation and Validation of Monoclonal Antibodies Suitable for Detecting and Monitoring Parvovirus Infections
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
Immune System Stimulation by Oncolytic Rodent Protoparvoviruses
Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors
Tailoring acyclovir prodrugs with enhanced antiviral activity: rational design, synthesis, human plasma stability and in vitro evaluation
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas
Oncolytic parvoviruses: from basic virology to clinical applications
Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
Double-faceted mechanism of parvoviral oncosuppression
ATNT-07FAVORABLE RESPONSE OF PATIENTS WITH GLIOBLASTOMA AT SECOND OR THIRD RECURRENCE TO REPEATED INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB
Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer
ET-21 * COMBINATION OF INTRAVENOUS AND INTRACEREBRAL INJECTION OF ONCOLYTIC PARVOVIRUS H-1 IN A PHASE I/IIA CLINICAL TRIAL OF PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: PENETRATION OF H-1 VIRUS ACROSS THE BLOOD-BRAIN BARRIER
Parvoviruses: The Friendly Anticancer Immunomodulator